DARWIN AG

Novogenia AG’s 2026 AGM reveals a €0.56 dividend, a strategic rename, and bold plans for genetic‑testing expansion, personalized supplements, and digital growth.

Darwin AG rebrands to Novogenia AG, approves a €0.56 dividend, and outlines 2026 growth in genomics‑based nutrition and cosmetics.

Darwin AG doubles 2025 revenue to €54.3 m, turns profitable with €53 m cash, and expands global partnerships—fueling sustainable growth in personalized healthcare.

Darwin AG, a German health care company, faces financial and ethical challenges as it navigates the complexities of genetic testing, personalized nutrition, and cosmetics, raising questions about its long-term viability and commitment to consumer tr…